Wang Ying-Xin, Lang Feng, Liu Yan-Xia, Yang Chang-Qing, Gao Heng-Jun
Tongji Institute of Digestive Disease, Department of Gastroenterology, Tongji Hospital, Tongji University Shanghai 200065, China.
National Engineering Center for Biochip at Shanghai 201023 China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):786-92. eCollection 2015.
MicroRNA-106b (miR-106b) is thought to be an oncogenic microRNA that promotes tumor growth and metastasis. The potential predictive value of miR-106b was studied in colonic cancer patients.
The expression of miR-106b was examined in 180 colonic cancer cases using in situ hybridization (ISH) technique and was evaluated semi-quantitatively by examining the staining index. The Correlation of miR-106b expression and clinic-pathological features was analyzed by Spearman Rank Correlation. Wilcoxon signed rank test was used for assessing the expression difference of miRNA-106b between colonic cancerous and para-cancerous ones, and their effects on patient survival were analyzed by a log-rank test and the Kaplan-Meier method.
MiR-106b was higher expressed in para-cancerous tissues, compared with colonic cancerous ones (P < 0.001). A positive correlation of miR-106b levels between colonic and para-cancerous tissues was also observed (CC = 0.523, P < 0.001). Furthermore, the expression of miR-106b was not significantly correlated with clinic-pathological parameters, including gender, age, histological grade, tumor size, pT stage, pN stage, pM stage and pTNM stage of the patients. Histological grade was positively correlated with pT stage (P = 0.011), pN stage (P = 0.036) and pTNM stage (P = 0.009). Patients expressing high levels of miR-106b both in colonic cancer tissues and para-cancerous ones have a relatively longer survival time but the difference is not statistically significant (P = 0.16).
The expression difference of miR-106b levels between colonic tissues and para-cancerous tissues is statistically significant, but the miR-106b levels were not quite correlated with clinic-pathological characteristics and overall survival times of patients with colonic cancer. Lower levels of miR-106b may be connected with neoplastic effects due to interference with TGF-β signaling, providing evidence that down-regulation of miR-106b might also play an important role in the progression of the disease. The study results are consistent with the literature and support the notion that miR-106b is an oncogenic microRNA.
微小RNA-106b（miR-106b）被认为是一种致癌性微小RNA，可促进肿瘤生长和转移。本研究探讨了miR-106b在结肠癌患者中的潜在预测价值。
采用原位杂交（ISH）技术检测180例结肠癌患者中miR-106b的表达，并通过检测染色指数进行半定量评估。采用Spearman等级相关分析miR-106b表达与临床病理特征的相关性。采用Wilcoxon符号秩和检验评估miR-106b在癌组织和癌旁组织中的表达差异，并采用对数秩检验和Kaplan-Meier法分析其对患者生存的影响。
与癌组织相比，癌旁组织中miR-106b表达较高（P<0.001）。同时观察到癌组织和癌旁组织中miR-106b水平呈正相关（CC=0.523，P<0.001）。此外，miR-106b的表达与患者的性别、年龄、组织学分级、肿瘤大小、pT分期、pN分期、pM分期和pTNM分期等临床病理参数无显著相关性。组织学分级与pT分期（P=0.011）、pN分期（P=0.036）和pTNM分期（P=0.009）呈正相关。在癌组织和癌旁组织中均高表达miR-106b的患者生存时间相对较长，但差异无统计学意义（P=0.16）。
miR-106b在结肠组织和癌旁组织中的表达差异具有统计学意义，但miR-106b水平与结肠癌患者的临床病理特征及总生存时间无明显相关性。miR-106b水平降低可能与干扰TGF-β信号传导的肿瘤形成效应有关，这为miR-106b下调在疾病进展中也可能起重要作用提供了证据。研究结果与文献一致，支持miR-106b是一种致癌性微小RNA的观点。
